The course is aimed at providing the student with a view of the biotechnological drugs already available for the treatment of various disease, and to provide the basis for the identification of new pharmacological targets and the design of novel biotechnological drugs.
Expected learning outcomes
At the end of the course the student will have a deep knowledge on the biotechnological drugs on the market, and she/he will be able to apply the knowledge to the identification of new targets and the design end evaluation of novel drugs.
Lesson period: Second semester
(In case of multiple editions, please check the period, as it may vary)
The course is structured in two parts 1. Role of biotechnologies in identifying new therapeutic targets: genomics, epigenetic, proteomics, metabolomics, animal models of human pathologies, organoids. 2. Biotechnological drugs. Pharmacokinetic of biotechnological drugs; drug development; pharmacology of metabolic disorders (dyslipidemia, diabetes, obesity); pharmacology of hemostasis (anticoagulant and antithrombotic drugs); replacement therapy (hormones, enzymes); antiviral therapies; antineoplastic drugs; gene therapy; cell therapy; nanotechnology.
Prerequisites for admission
The student must have knowledge in physiology, biochemistry, and molecular pharmacology (drug interaction with targets).
Ho RJY, Gibaldi M Biotechnology and Biopharmaceuticals Wiley-Liss
Vegeto E, Maggi A, Minghetti P Farmaci biotecnologici: aspetti farmacologici e clinici Casa Editrice Ambrosiana
Assessment methods and Criteria
The final evaluation consists in an oral examination, lasting approximately 30-40 minutes. The student must answer to questions on the topics discussed during the course, being able to comprehend problems associated with biotechnological drugs, and using appropriate language.